Kornimate/medical-research-clean huggingface dataset:
comparison of berberine and metformin for the treatment for ms in schizophrenia patients

Conditions: Schizophrenia; Metabolic Syndrome; Berberine; Metformin

Summary: berberine is an isoquinoline alkaloid extracted from medicinal herbs, has been demonstrated to produce beneficial effects on diabetes and hyperlipidemia, fewer study reported its modification on lipid metabolism in schizophrenia. metformin, have been used for metabolic abnormalities in schizophrenia, findings from these studies indicated that they did have some effect,which are still in experimental stage.this study is aim to compare the efficacy and safety of berberine and metformin for preventing metabolic dysfunction in schizophrenia patients.


Eligibility criteria:
inclusion criteria: * 1) in accordance with criteria set out in the structured clinical interview for diagnostic and statistical manual of mental disorders-fourth edition (dsm-iv )axis i disorders, clinical version; * 2)meet metabolic syndrome based on guidelines for prevention and treatment of blood lipid abnormality in chinese adults(2007); * 3)have taken stable dose of the current single antipsychotic drug for at least one month; * 4) female subjects will be enrolled to participate in the study if they are of non-childbearing potential or of child-bearing potential and willing to practice appropriate birth control methods during the study. exclusion criteria: * 1)individuals who refuse to provide informed consent; * 2)currently substance abuse or psychiatrically unstable per treating clinician's judgment; * 3)one with significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases also not suitable for this trial; * 4)currently on anti-inflammatory or immunosuppressant medication including oral steroids and history of chronic infection (including tuberculosis, hiv and hepatitis), malignancy, organ transplantation, blood dyscrasia, central nervous system demyelinating disorder, and any other known autoimmune or inflammatory condition pregnancy or breastfeeding.

Keywords: berberine metformin metabolic syndrome schizophrenia
a comparison of ropinirole immediate release with ropinirole prolonged release in patients with advanced parkinson's

Conditions: Parkinson Disease

Summary: this study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries. the new prolonged release formulation allows the drug to be taken once a day rather than three times a day. this study will also evaluate the side effects of the new prolonged release formulation of ropinirole


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of advanced idiopathic parkinson's disease (according to modified hoehn \& yahr criteria stages ii-iv) whose symptoms are not adequately controlled with l-dopa. exclusion criteria: * patients with late stage advanced parkinson's disease with incapacitating dyskinesias on a stable dose of l-dopa. * current, or history of, (within the previous 3 months), significant and/or uncontrolled psychiatric, haematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or active malignancy. * recent history of severe dizziness or fainting on standing. * dementia, neurotic behaviour, crippling degenerative arthritis or limb amputations, or prior or current major psychosis. * recent history or current evidence of drug abuse or alcoholism. * use of a dopamine agonist within 4 weeks of starting the study. * personal or family history of an allergic reaction to ropinirole.

Keywords: safety efficacy l-dopa ropinirole pr parkinson's disease ropinirole ir adjunctive therapy superiority requip health outcomes
efficacy, safety, tolerability of axa1125 in fatigue after covid-19 infection

Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

Summary: this study will compare the effects of axa1125, an orally active mixture of amino acids, compared to placebo, on improving muscle function (metabolism) following moderate exercise in subjects with fatigue-predominant post-acute sequelae of sars-cov-2 as well as the safety and tolerability of axa1125. subjects will take one dose of axa1125 or a placebo twice daily for 28 days.


Eligibility criteria:
inclusion criteria: * willing to participate in the study and provide written informed consent * male and female adults aged \> 18 years and less than 65 years * must have had clinically suspected covid-19 and a positive antibody test or a documented sars-cov-2 infection (a positive reverse transcription polymerase chain reaction test) at least 12 weeks prior to screening * must have fatigue-predominant pasc * other than pasc, a subject must be in good health without other significant medical or not well controlled medical or psychiatric conditions exclusion criteria: * other than pasc, have an explanation for fatigue * other than pasc, a history or presence of an uncontrolled, clinically significant disease * medical history that includes of non-invasive or invasive ventilatory support for covid 19, intensive care unit or other high dependency unit admission for covid-19, hospitalization for \>1 week for covid-19 without intubation

Keywords: long covid long-haul covid muscle weakness covid pasc fatigue amino acids bioenergetics mitochondrial dysfunction phosphocreatine recovery exertional fatigue phospho magnetic resonance spectroscopy skeletal muscle
proclaim-cx-2009: a trial to find safe and active doses of an investigational drug cx-2009 for patients with selected solid tumors

Conditions: Solid Tumor, Adult; Breast Cancer; Non Small Cell Lung Cancer; Head and Neck Cancer; Ovarian Cancer

Summary: the purpose of this first-in-human study of cx-2009 is to characterize the safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd) and antitumor activity of cx-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. proclaim: probody clinical assessment in man cx-2009 clinical trial 001 probody is a trademark of cytomx therapeutics, inc


Eligibility criteria:
inclusion criteria: 1. histologically confirmed diagnosis of metastatic or locally advanced unresectable tumors 2. patients demonstrating disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, 3. agreement to provide mandatory archival tissue or fresh biopsy. 4. at least 18 years of age. exclusion criteria: 1. active or chronic corneal disorder, history of corneal transplantation, active herpetic keratitis, and active ocular conditions requiring ongoing treatment/monitoring 2. serious concurrent illness, including clinically relevant active infection 3. history of or current active autoimmune diseases 4. significant cardiac disease such as recent myocardial infarction 5. history of multiple sclerosis or other demyelinating disease, eaton-lambert syndrome (para-neoplastic syndrome), history of hemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease; 6. non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm; 7. history of severe allergic or anaphylactic reactions to previous monoclonal antibody therapy; 8. currently receiving anticoagulation therapy with warfarin; 9. major surgery (requiring general anesthesia) within 3 months prior to dosing.

Keywords: cancer solid tumor proclaim cx-2009 probody™ therapeutic drug conjugate antibody drug conjugate cd166
effectiveness of carpal ligament self-myofascial stretching in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts), also known as median mononeuropathy, occurs when the median nerve is squeezed or compressed as it travels through the carpal tunnel at the wrist. it is common in the age group of 40-60 years. the main aim of the study was to compare the effectiveness of carpal ligament self-myofascial stretching over conventional physical therapy on reducing pain and improving function in patients with stage i and ii cts-thirty-six subjects with stage i and ii (mild) cts were recruited. thirty-six subjects who fulfilled the inclusion criteria were randomly assigned to the experimental group and control group, with 18 patients in each group. the experimental group received carpal ligament self-myofascial stretching along with conventional physical therapy, while the control group received traditional physical therapy alone. the duration of the treatment was six weeks. the outcome measures used were the boston carpal tunnel questionnaire and the visual analogue scale.


Eligibility criteria:
inclusion criteria: * patients diagnosed with cts between age group 30 - 60 years. * patients with stage i and ii (mild) cts, confirmed by nerve conduction study (emg diagnosed by a medical professional). * patients who are able to read and understand english. exclusion criteria: * presence of polyneuropathy. * consistent use of adaptive equipment, such as wheel chair or cane. * patients presenting with shoulder pathologies. * patients with other neurological or musculoskeletal conditions including cervical radiculopathy, history of wrist and hand fractures, upper extremity joint dislocations, brachial plexus injuries, cubital tunnel syndrome, rheumatoid arthritis, de quervain's tenosynovitis, cut injuries of hand. * patients who have underwent recent carpal tunnel release (within 1 year).

Keywords: myo-fascial stretching pain function
intrastromal corneal ring segments and toric phakic posterior intra-ocular lenses implantation in keratoconus

Conditions: Keratoconus

Summary: to compare visual and refractive measurements of intrastromal corneal ring segments versus toric phakic posterior intra-ocular lenses implantation in keratoconus

* the study is a prospective comparative interventional case series. it will be conducted in minia university hospital and roaa laser vision correction center. * fourty eyes will be evenly allocated into two groups: group (a): 20 eyes will undergo corneal collagen cross linking (epithelium off) 1 month after femtosecond laser assisted intrastromal corneal keraring segments. group (b): 20 eyes will undergo toric phakic posterior iol implantation 1 year after corneal collagen cross linking (epithelium off). • an informed written consent to be involved in the study will be obtained from each patient.

Eligibility criteria:
inclusion criteria: * keratoconus grade i to iii according to the amsler-krumeich classification exclusion criteria: * acute hydrops or grade iv keratoconus * any ocular diseases or surgeries * corneal thickness less than 400 µm at the thinnest corneal point, and at least 450 µm at the incision site for icrs group * corneal pacities
ibuprofen/acetaminophen versus nurofen plus® and panadeine® extra dental pain study

Conditions: Post-operative Pain

Summary: the objective is to assess the efficacy and tolerability of a combination of 400 mg ibuprofen plus 1000 mg acetaminophen, 200 mg ibuprofen plus 500 mg acetaminophen compared with nurofen plus® and panadeine® extra.

rb has developed a fixed-dose combination of ibuprofen and acetaminophen (paracetamol). since the pharmacological actions of ibuprofen and acetaminophen (paracetamol) differ in their site and mode of action, the combination would be expected to be more effective than either active alone, given that pain is multi-factorial with different mediators. the purpose of this study was to compare the efficacy and tolerability of ibuprofen/acetaminophen (paracetamol) combination with leading market analgesics. the efficacy and tolerability was assessed in terms of total analgesic effect, peak analgesic effect, onset and duration of action and the subject's overall assessment of the study medication.

Eligibility criteria:
main inclusion criteria: experiencing moderate to severe pain after extraction of impacted third molars main exclusion criteria: any ongoing painful condition other than that associated with the current third molar surgery that could significantly interfere with the subject's suitability any condition that would render the subject unsuitable to receive an nsaid, acetaminophen or codeine

Keywords: dental pain ibuprofen acetaminophen nurofen plus® panadeine® extra paracetamol
soluble cd146 and proteinuria in chronic renal disease

Conditions: Chronic Renal Failure

Summary: chronic renal disease (ckd) is defined as a decrease in glomerular filtration rate (gfr) and / or proteinuria or albuminuria (a protein present in urine). albuminuria is considered a marker of endothelial dysfunction. proteinuria and / or albuminuria are recognized as cardiovascular risk factors in both diabetic and non-diabetic populations, independently of gfr. it is also a marker of progression of kidney disease. cluster of differentiation 146 (cd146) is an endothelial adhesion molecule with preferential localization in the junction. soluble cd146 (or cd146s). cd146s is a biomarker of endothelial dysfunction that is easy to assay. the increase in cd146 levels was described during the mrc, especially in diabetic patients with significant proteinuria. in two independent cohorts of patients with cdr, cd146s did not correlate with creatinine or gfr but appeared to correlate with proteinuria. the aim of our study is to determine whether the blood concentration of cd146s is correlated with proteinuria independently of gfr. for this purpose, we propose this study in the kidney nephrology and transplantation center of conception hospital, with the objective of highlighting the link between proteinuria and serum cd146 levels in patients with ckd, whatever their renal function and / or underlying pathology. 205 patients will be included over two years with dosing of cd146s and proteinuria at the same time. these 205 patients will be recruited at each stage of the ckd (41 in each arm). cd146s could be a new biomarker predicting the risk of renal function impairment or cardiovascular risk independent of renal function.


Eligibility criteria:
inclusion criteria: * adult subject aged 18 years or over * subject capable of giving informed consent * patient with chronic kidney disease (stage 1 to 5 ckd regardless of etiology) exclusion criteria: * pregnant or lactating woman * person deprived of liberty or hospitalized without consent * major under legal protection or unable to express his consent * refusal of the patient * patient with a history of kidney transplantation * evolutionary cancer
renal arteries dysplastic aneurysms: anatomopathological and genetic study

Conditions: Fibromuscular Dysplasia; Renal Artery Stenosis

Summary: fibromuscular dysplasia (fmd) is localized structural defects in the arterial wall, whose innate or acquired character is still unknown. this segmental non atheromatous injury, leads to stenosis of the arteries of small and medium caliber. renal arteries are the most commonly affected with 60-75% of total fibrodysplasia. three histological subtypes have been described: intimal, medial and peri-medial. they are not mutually exclusive and can be observed in the same patient. this is a rare blood disease, occurring in children and young adults. in this young population with long life expectancy, these aneurysmal lesion are associated with 10% risk of rupture. to date, no data have shown in the literature that fmd is link to genetic causes, or if there is specific histopathologic lesions for non-atherosclerotic renal artery aneurysms. to answer these questions, cardiovascular surgery unit of the university hospital of saint-etienne, french national reference center for renal artery surgery, in association with the reference center for rare vascular disease in paris, designed the first study for pathological and genetic characteristics of dysplastic renal artery aneurysms in young patients.


Eligibility criteria:
inclusion criteria: * patients with one or more renal artery aneurysm (raa), not eligible for endovascular treatment, have been operated at the hospital of saint-etienne, with tissue (adjacent part and aneurysm) cryopreserved in liquid nitrogen in renal lab and then sent in genetic lab in georges pompidou european hospital (ehgp ). * patient (or parent/person having parental authority) affiliate or entitled to a social security scheme. * signature of patient consent (or parents or holder of parental authority) exclusion criteria: * patient not included in the tissue collection in georges pompidou european hospital (ehgp ). * patient refusing to participate in the study and / or genetic analysis or, for juvenile patients, parents or holder of parental authority refusing the minor patient to be involved in the study and / or genetic analysis. * patient with fmd whose samples in the tissue collection did not concern aneurysm.

Keywords: fibromuscular dysplasia dysplastic renal artery aneurysm renal artery aneurysms non atheromatous dysplastic anatomopathologic genetic
effects of cannabis on prescription drug abuse liability and analgesia

Conditions: Pain; Abuse, Drug

Summary: the purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.


Eligibility criteria:
inclusion criteria: * male or non-pregnant female aged 21-53 years * previous cannabis use * previous opioid use * urine test positive for recent cannabis use * being able to perform all study procedures * currently practicing an effective form of birth control (women only) exclusion criteria: * meeting criteria for some use disorders * report regular illicit drug use * if medical history, physical and psychiatric examination, or laboratory tests performed during the screening process revealed any significant illness

Keywords: experimental pain cannabis cannabidiol thc
safety and effects of slx-2101 taken for up to 14 days on blood pressure in patients with hypertension

Conditions: Hypertension

Summary: the purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.

1. office seated peripheral systolic and diastolic blood pressure 2. adverse events and vital signs 3. plasma concentrations of slx-2101

Eligibility criteria:
inclusion criteria: * male or females between 18 and 80 years, inclusive * moderate to severe hypertension * body weight within a body mass index range of 18 - 32 kg/m2 exclusion criteria: * subject is receiving more than four antihypertensive agents * history of drug abuse * exposure to a new chemical entity within 3 months prior to the first day of dosing
tolerability and efficacy of sodium picosulfate/magnesium citrate versus peg/ascorbic acid in ulcerative colitis patients

Conditions: Ulcerative Colitis

Summary: ulcerative colitis is a chronic condition that results in the inflammation of the colon and rectum. patients suspected to have ulcerative colitis are diagnosed via colonoscopy. moreover, colonoscopy is considered to be the preferred procedure for assessing the activity and extent of the disease, as well as monitoring treatment response and development of lesions. therefore, optimal performance and visualization of mucosal lesions via adequate bowel preparation is essential in such patients. in addition, the nature of the disease and the need for multiple colonoscopies throughout a patient's lifetime makes compliance to repeated procedures difficult. it is well known that colonoscopy preparations are generally poorly tolerated, disliked and, consequently serve as an additional burden on patients.polyethylene glycol (peg), despite being the golden standard, is not very well tolerated. inadequate bowel preparations are associated with cancelled procedures, prolonged procedure time, incomplete examination, increased cost and possibly complications, physician frustration and patient anxiety, but most importantly, with missed pathology. a good bowel preparation would need a solution with reasonable volume, acceptable taste, minimal diet restrictions, and easy-to-follow instructions. the strict need for adherence to drinking a relatively large volume of solution preparation may result in poor compliance. despite the emergence of several types of low volume preparations, the evidence on the use of such solutions remains sparse. this is especially true in terms of patients' tolerability to the solution, and its relation with adequate bowel preparation during colonoscopy. the investigator's aim is to assess how small volume preparations such as sodium picosulfate/magnesium citrate (citrafleet®) enhance participants tolerability to the solution, compliance, and adequacy of bowel preparations when compared to 2l polyethylene glycol + ascorbic acid (moviprep®) in patients with ulcerative colitis.


Eligibility criteria:
inclusion criteria: * patients diagnosed with ulcerative colitis * patients undergoing elective outpatient colonoscopy * patients consenting to the study exclusion criteria: * age less than 18 years * pregnant or lactating women * significant gastroparesis * gastric outlet obstruction * ileus * known or suspected bowel obstruction or perforation * phenylketonuria * toxic colitis or megacolon * having a stoma * compromised swallowing reflex or mental status * psychiatric disease or known or suspected poor compliance * severe chronic renal failure (creatinine clearance \<30 ml/minute) * severe congestive heart failure (new york heart association \[nyha\] class iii or iv) * dehydration * laxative use or dependency * chronic constipation (\<3 spontaneous bm/week) * uncontrolled hypertension (systolic blood pressure ≥170 mm hg, diastolic blood pressure ≥100 mm hg) * prior colon resection * age above 65 years * profusely bleeding patients with severe uc